MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12933-023-01744-4

Медицинская библиотека · Cardiovascular diabetology · 2023

Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial.

Chiarito Mauro, Sanz-Sanchez Jorge, Piccolo Raffaele, Condello Francesco, Liccardo Gaetano, Maurina Matteo, Avvedimento Marisa, Regazzoli Damiano, Pagnotta Paolo, Garcia-Garcia Hector M, Mehran Roxana, Federici Massimo, Condorelli Gianluigi, Diez Gil Jose Luis, Reimers Bernhard, Ferrante Giuseppe, Stefanini Giulio

Клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiography in terms of significant increase in lactate levels.

METHODS

In this open-label, prospective, multicentre, single-arm trial, all diabetic patients undergoing coronary angiography with or without percutaneous coronary intervention at 3 European centers were screened for enrolment. The primary endpoint was the increase in lactate levels from preprocedural levels at 72-h after the procedure. Secondary endpoints included contrast associated-acute kidney injury (CA-AKI), M-ALA, and all-cause mortality.

RESULTS

142 diabetic patients on metformin therapy were included. Median preprocedural lactate level was 1.8 mmol/l [interquartile range (IQR) 1.3-2.3]. Lactate levels at 72 h after coronary angiography were 1.7 mmol/l (IQR 1.3-2.3), with no significant differences as compared to preprocedural levels (p = 0.91; median difference = 0; IQR - 0.5 to 0.4 mmol/l). One patient had 72-h levels ≥ 5 mmol/l (5.3 mmol/l), but no cases of M-ALA were reported. CA-AKI occurred in 9 patients (6.1%) and median serum creatinine and estimated glomerular filtration rate remained similar throughout the periprocedural period. At a median follow-up of 90 days (43-150), no patients required hemodialysis and 2 patients died due to non-cardiac causes.

CONCLUSIONS

In diabetic patients undergoing invasive coronary angiography, metformin continuation throughout the periprocedural period does not increase lactate levels and was not associated with any decline in renal function.

TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov (NCT04766008).

Для цитирования: Chiarito Mauro, Sanz-Sanchez Jorge, Piccolo Raffaele, Condello Francesco, Liccardo Gaetano, Maurina Matteo, Avvedimento Marisa, Regazzoli Damiano, Pagnotta Paolo, Garcia-Garcia Hector M, Mehran Roxana, Federici Massimo, Condorelli Gianluigi, Diez Gil Jose Luis, Reimers Bernhard, Ferrante Giuseppe, Stefanini Giulio. Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial.. Cardiovascular diabetology. 2023. DOI: 10.1186/s12933-023-01744-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.